These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 33917006)
1. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Han S; Woo S; Kim YI; Lee JL; Wibmer AG; Schoder H; Ryu JS; Vargas HA Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917006 [TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
7. Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559 [TBL] [Abstract][Full Text] [Related]
8. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
9. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis. Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449 [TBL] [Abstract][Full Text] [Related]
10. Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. Weber M; Hadaschik B; Ferdinandus J; Rahbar K; Bögemann M; Herrmann K; Fendler WP; Kesch C Eur Urol Focus; 2021 Mar; 7(2):279-287. PubMed ID: 33483289 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients. Özülker T; Özülker F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026 [TBL] [Abstract][Full Text] [Related]
12. Preliminary results on response assessment using Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography. Gupta M; Choudhury PS; Rawal S; Goel HC; Rao SA Urol Ann; 2019; 11(2):155-162. PubMed ID: 31040600 [TBL] [Abstract][Full Text] [Related]
14. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
15. Early Prostate-Specific Antigen Changes and Clinical Outcome After Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687 [TBL] [Abstract][Full Text] [Related]
17. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246 [No Abstract] [Full Text] [Related]
18. Mesci A; Ahmadi E; Ali A; Gouran-Savadkoohi M; Evelyn Tsakiridis E; Biziotis OD; Chow T; Kapoor A; Sur M; Steinberg GR; Liu S; Zukotynski K; Tsakiridis T Clin Transl Radiat Oncol; 2023 Mar; 39():100583. PubMed ID: 36713978 [TBL] [Abstract][Full Text] [Related]
19. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with Hotta M; Gafita A; Czernin J; Calais J J Nucl Med; 2022 Oct; 63(10):1484-1488. PubMed ID: 35273096 [TBL] [Abstract][Full Text] [Related]
20. Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. Fankhauser CD; Poyet C; Kroeze SGC; Kranzbühler B; Schüler HIG; Guckenberger M; Kaufmann PA; Hermanns T; Burger IA World J Urol; 2019 Mar; 37(3):457-467. PubMed ID: 30030659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]